NCT01983410进行中（未招募）不适用
A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 600
- 试验地点
- 13
- 主要终点
- prospective Registry
研究概览
简要总结
The purpose of this study is to better understand why pancreatic cancer develops in some people who are known carriers of the gene mutation (an abnormality) called BRCA, or its close relative PALB2. The investigators hope to do this by establishing a BRCA/PALB2 mutation carriers Pancreatic Ductal Adenocarcinoma (the common form of pancreatic cancer) Registry. A registry is a database of information.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •BRCA mutation carrier is defined as a person with any mutation of the BRCA gene, including BRCA1, or BRCA
- •PALB2mut patients are also eligible.
- •Relative of a BRCA PDAC patient is defined as a first-degree relative, which includes, parents, siblings or children.
- •BRCAmut PDAC Group: Study Group A: Ashkenazi Jewish descent
- •Known BRCA mutation carrier.
- •Ashkenazi Jewish Descent (at least one parent of Ashkenazi Jewish origin).
- •Histologic proof of primary pancreatic ductal adenocarcinoma.
- •May have either potentially curable (resectable) primary PDAC, localized but unresectable primary PDAC, or metastatic (stage IV) PDAC.
- •Prior personal history of other malignancy; either prior or currently active, including breast , ovarian or prostate cancer is allowed.
- •Both previously treated and previously untreated patients are eligible. Previous treatment may include surgical resection, regional radiation therapy, or systemic therapy. Patient may be receiving active therapy.
- •Willing to provide blood specimens for correlative studies.
- •Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material). New tumor biopsies are not required for entrance into the Registry.
- •BRCAmut PDAC Group: Study Group B: non-Ashkenazi Jewish descent
- •Know n BRCA mutation carrier.
- •Histologic proof of primary pancreatic ductal adenocarcinoma.
- •May have either potentially curable (resectable) primary PDAC, localized but unresectable primary PDAC, or metastatic (stage IV) PDAC.
- •Prior personal history of other malignancy; either prior or currently active, including breast, ovarian, or prostate cancer is allowed.
- •Both previously treated and previously untreated patients are eligible. Previous treatment may include surgical resection, regional radiation therapy, or systemic therapy. Patient may be receiving active therapy.
- •Willing to provide blood specimens for correlative studies.
- •Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material). New tumor biopsies are not required for entrance into the Registry.
- •BRCA mutation carrier, relative of a BRCA PDAC patients, without PDAC or other BRCAmut related malignancy: (Control Cohort 1A): Ashkenazi Jewish descent
- •Known BRCA mutation carrier.
- •Ashkenazi Jewish Descent (at least one parent of Ashkenazi Jewish origin).
- •No current or prior history of PDAC.
- •Relative of a BRCAmut PDAC patient; no prior or active personal history of breast, ovarian, or prostate cancer
- •Willing to provide blood specimens for correlative studies.
- •BRCA mutation carrier, relative of a BRCA PDAC patients, without PDAC or other BRCAmut related malignancy: (Control Cohort 1B): non-Ashkenazi Jewish descent
- •Know n BRCA mutation carrier.
- •No current or prior history of PDAC.
- •First or second degree relative of a BRCAmut PDAC patient; no prior or active personal history of breast, ovarian, or prostate cancer.
- •Willing to provide blood specimens for correlative studies.
- •BRCAmut Carrier relative of a BRCAmut PDAC patient who themselves have prior or active BRCAmut related malignancy (Control Cohort 2A):Ashkenazi Jewish descent
- •Known BRCA mutation carrier.
- •Ashkenazi Jewish Descent (at least one parent of Ashkenazi Jewish origin).
- •No current or prior history of PDAC.
- •Relative of a BRCAmut PDAC patient.
- •Prior or active personal history of any BRCA-related cancer.
- •Willing to provide blood specimens for correlative studies.
- •BRCAmut Carrier relative of a BRCAmut PDAC patient who themselves have prior or active BRCAmut related malignancy (Control Cohort 2B): non-Ashkenazi Jewish descent
- •Know n BRCA mutation carrier.
- •No current or prior history of PDAC.
- •First or second degree relative of a BRCAmut PDAC patient.
- •Prior or active personal history of any BRCA-related cancer.
- •Willing to provide blood specimens for correlative studies.
- •BRCAmut carrier who is not related to a BRCAmut PDAC patient: (Control cohort 3A) Ashkenazi Jewish descent
- •Known BRCAmut carrier.
- •Ashkenazi Jewish decent (at least one parent of Ashkenazi Jewish origin).
- •No current or prior personal history of PDAC.
- •Prior personal history of other malignancy including breast, ovarian or prostate cancer is allowed.
- •Willing to provide blood specimens for correlative studies.
- 另有 12 项未显示
排除标准
- •Individuals will be excluded from the Registry if they:
- •Are unable to sign informed consent for medical or other reasons. Do not speak English (MSK and UPenn) or do not speak English or Hebrew (BCGC Sites).
- •Are under 21 years of age.
- •Not willing to provide blood samples for correlative studies.
结局指标
主要结局
prospective Registry
时间窗: 3 years
Establishment of a BRCA mutation carriers PDAC Registry with appropriate control groups, and collection and storage of biological material for future studies.
次要结局
未报告次要终点
研究者
研究点 (13)
Loading locations...
相似试验
进行中（未招募）
不适用
Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized TherapyPancreatic CancerNCT03060720Dana-Farber Cancer Institute271
进行中（未招募）
不适用
Pancreatic Cancer Genetic Epidemiology (PACGENE) StudyPancreatic CancerNCT00526578M.D. Anderson Cancer Center4,770
进行中（未招募）
不适用
Clinical Significance of Germline BRCA MutationsOvarian CancerBreast CancerNCT00579488Memorial Sloan Kettering Cancer Center13,320
招募中
不适用
A Pancreatic Cancer Screening Study in Hereditary High Risk IndividualsPancreatic NeoplasmsNCT03250078Nuvance Health200
招募中
不适用
Pancreatic Cancer GeneticsPancreatic CancerNCT01102569Columbia University100